Valuation: IntoCell, Inc.

Market Cap 307B 221M 190M 177M 162M 305M 21.12B 310M 2.09B 818M 10.59B 830M 812M 35.02B P/E 2024 *
-
P/E 2025 -77.1x
Enterprise Value 287B 206M 177M 165M 152M 285M 19.7B 290M 1.95B 763M 9.88B 774M 757M 32.67B EV / Sales 2024 *
-
EV / Sales 2025 365,559,272x
Free-Float
78.73%
Yield 2024 *
-
Yield 2025 -
1 day-2.39%
1 week-4.22%
Current month+26.39%
1 month-7.05%
3 months-32.73%
6 months-60.37%
Current year-64.37%
1 week 20,050
Extreme 20050
22,850
1 month 13,050
Extreme 13050
23,500
Current year 13,050
Extreme 13050
63,500
1 year 13,050
Extreme 13050
74,900
3 years 13,050
Extreme 13050
74,900
5 years 13,050
Extreme 13050
74,900
10 years 13,050
Extreme 13050
74,900
Manager TitleAgeSince
Chief Executive Officer 66 2015-03-31
Director of Finance/CFO 69 2019-05-31
Chief Tech/Sci/R&D Officer 58 2021-03-31
Director TitleAgeSince
Director/Board Member 69 2020-03-19
Director/Board Member 66 2015-03-31
Director/Board Member 58 2021-03-31
Date Insider Type Main position Quantity % Market Cap.
7/15/25 Buy

Founder

10,000 0.0674%
7/15/25 Buy

Founder

26,000 0.1751%
5/28/25 Free 40,400 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.39%-4.22%-20.12% - 221M
+2.37%+2.30%+3.39%+22.74% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+1.44%+1.52%+4.22%+31.00% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +1.73%+1.39%+73.07%+128.44% 27.48B
Weighted average by Cap. +1.87%+2.37%+104.79%+154.15%

Financials

2024 2025
Net sales 2.91K 2.09 1.79 1.67 1.54 2.89 199.72 2.94 19.75 7.73 100.17 7.85 7.68 331.18 2.3K 1.65 1.42 1.32 1.22 2.29 158.06 2.32 15.63 6.12 79.27 6.21 6.07 262.11
Net income -9.91B -7.13M -6.12M -5.71M -5.24M -9.85M -681M -10.02M -67.39M -26.39M -342M -26.77M -26.19M -1.13B -10.6B -7.63M -6.54M -6.11M -5.6M -10.54M -729M -10.71M -72.08M -28.23M -366M -28.64M -28.01M -1.21B
Net Debt -2.15B -1.54M -1.32M -1.24M -1.13M -2.13M -148M -2.17M -14.59M -5.71M -73.99M -5.8M -5.67M -245M -20.59B -14.81M -12.7M -11.86M -10.88M -20.46M -1.42B -20.8M -140M -54.8M -710M -55.6M -54.39M -2.35B
Logo IntoCell, Inc.
IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.
Employees
-
Date Price Change Volume
26-08-19 ₩20,450.00 -2.39% 47,031
26-08-18 ₩20,950.00 -5.84% 54,208
26-08-14 ₩22,250.00 +2.06% 40,005
26-08-13 ₩21,800.00 +2.11% 40,824
26-08-12 ₩21,350.00 +0.71% 36,712

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A287840 Stock